NASDAQ:FLGT Fulgent Genetics (FLGT) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free FLGT Stock Alerts $21.69 +0.06 (+0.28%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$21.63▼$21.9950-Day Range$21.55▼$26.4552-Week Range$21.23▼$44.09Volume173,742 shsAverage Volume213,052 shsMarket Capitalization$645.93 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Fulgent Genetics alerts: Email Address Fulgent Genetics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside38.3% Upside$30.00 Price TargetShort InterestHealthy3.19% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment-0.17Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.04) to ($1.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.15 out of 5 starsMedical Sector182nd out of 939 stocksMedical Laboratories Industry7th out of 19 stocks 3.0 Analyst's Opinion Consensus RatingFulgent Genetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.00, Fulgent Genetics has a forecasted upside of 38.3% from its current price of $21.69.Amount of Analyst CoverageFulgent Genetics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.19% of the float of Fulgent Genetics has been sold short.Short Interest Ratio / Days to CoverFulgent Genetics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fulgent Genetics has recently increased by 22.63%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFulgent Genetics does not currently pay a dividend.Dividend GrowthFulgent Genetics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFulgent Genetics has received a 58.06% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Private genetic testing services", "Private infectious disease diagnostics services", and "Private medical laboratory services" products. See details.Environmental SustainabilityThe Environmental Impact score for Fulgent Genetics is -0.67. Previous Next 1.6 News and Social Media Coverage News SentimentFulgent Genetics has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Fulgent Genetics this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows7 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fulgent Genetics insiders have not sold or bought any company stock.Percentage Held by Insiders31.76% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Fulgent Genetics are expected to grow in the coming year, from ($2.04) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulgent Genetics is -3.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulgent Genetics is -3.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulgent Genetics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About Fulgent Genetics Stock (NASDAQ:FLGT)Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Read More FLGT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FLGT Stock News HeadlinesMarch 24, 2024 | americanbankingnews.comFulgent Genetics (NASDAQ:FLGT) Hits New 12-Month Low at $21.26March 16, 2024 | finance.yahoo.comFLGT Apr 2024 20.000 callMarch 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 1, 2024 | seekingalpha.comFulgent Genetics (FLGT) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comFulgent Genetics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 1, 2024 | finance.yahoo.comAn Intrinsic Calculation For Fulgent Genetics, Inc. (NASDAQ:FLGT) Suggests It's 32% UndervaluedFebruary 29, 2024 | insidermonkey.comFulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | finance.yahoo.comQ4 2023 Fulgent Genetics Inc Earnings CallMarch 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.February 28, 2024 | markets.businessinsider.comHere's what to expect from Fulgent Genetics's earnings reportFebruary 28, 2024 | finance.yahoo.comFulgent Genetics Inc (FLGT) Faces GAAP Loss Despite Core Revenue Growth in 2023February 28, 2024 | businesswire.comFulgent Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 21, 2024 | seekingalpha.comFulgent Genetics: Buy Growth Ahead Below Liquidation ValueFebruary 17, 2024 | finance.yahoo.comFLGT Mar 2024 30.000 callFebruary 17, 2024 | finance.yahoo.comFLGT Mar 2024 35.000 putFebruary 13, 2024 | finance.yahoo.comFulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024February 12, 2024 | msn.comCooperSurgical and Fulgent partner on newborn genetic screening panelsDecember 3, 2023 | finance.yahoo.comThe 3 Best Digital Health Stocks for Personalized MedicineDecember 1, 2023 | seekingalpha.comFollowing Up On Fulgent GeneticsNovember 14, 2023 | businesswire.comFulgent to Participate in the Piper Sandler 35 th Annual Healthcare ConferenceNovember 14, 2023 | finance.yahoo.comFulgent to Participate in the Piper Sandler 35th Annual Healthcare ConferenceNovember 5, 2023 | finance.yahoo.comFulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2023 Earnings Call TranscriptNovember 3, 2023 | finance.yahoo.comQ3 2023 Fulgent Genetics Inc Earnings CallNovember 3, 2023 | finance.yahoo.comFulgent Shares Data from Two Poster Presentations at SITC 2023 Annual MeetingNovember 3, 2023 | finance.yahoo.comFulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Tops Revenue EstimatesNovember 3, 2023 | finance.yahoo.comFulgent Genetics Inc (FLGT) Reports Q3 2023 Financial ResultsNovember 3, 2023 | markets.businessinsider.comFulgent Genetics Reports Loss In Q3 On Lower RevenueSee More Headlines Receive FLGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/28/2024Next Earnings (Estimated)5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:FLGT CUSIPN/A CIK1674930 Webwww.fulgentgenetics.com Phone(626) 350-0537Fax626-454-1667Employees1,184Year Founded2011Price Target and Rating Average Stock Price Target$30.00 High Stock Price Target$35.00 Low Stock Price Target$25.00 Potential Upside/Downside+38.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-167,820,000.00 Net Margins-58.03% Pretax Margin-60.19% Return on Equity-3.04% Return on Assets-2.81% Debt Debt-to-Equity RatioN/A Current Ratio6.96 Quick Ratio6.96 Sales & Book Value Annual Sales$289.21 million Price / Sales2.23 Cash Flow$3.18 per share Price / Cash Flow6.82 Book Value$38.24 per share Price / Book0.57Miscellaneous Outstanding Shares29,780,000Free Float20,325,000Market Cap$645.93 million OptionableOptionable Beta1.45 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Ming Hsieh (Age 68)Chairman & CEO Comp: $1.66MMr. Jian Xie (Age 58)COO & President Comp: $755.73kMr. Paul Kim (Age 57)Chief Financial Officer Comp: $757.59kDr. Hanlin Gao D.A.B.M.G. (Age 57)FACMG, M.D., Ph.D., Chief Scientific Officer & Laboratory Director Comp: $630.61kMs. Natalie PrescottGeneral Counsel & Chief Privacy OfficerMs. Doreen NgVP of Operations & Compliance and GM of Houston OfficeMr. Jakub SramVice President of Business Development & SalesMs. Ellen TsuiVice President of Human ResourcesMr. Brandon PerthuisChief Commercial OfficerDr. Lawrence M. Weiss M.D. (Age 67)Chief Medical Officer More ExecutivesKey CompetitorsCastle BiosciencesNASDAQ:CSTLCareDxNASDAQ:CDNACelcuityNASDAQ:CELCSera PrognosticsNASDAQ:SERAViridian TherapeuticsNASDAQ:VRDNView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 22,480 shares on 3/11/2024Ownership: 4.755%Goldman Sachs Group Inc.Sold 1,290 shares on 3/1/2024Ownership: 0.346%Price T Rowe Associates Inc. MDBought 1,448 shares on 2/16/2024Ownership: 0.036%Price T Rowe Associates Inc. MDBought 1,448 shares on 2/15/2024Ownership: 0.036%Gotham Asset Management LLCSold 3,553 shares on 2/15/2024Ownership: 0.036%View All Insider TransactionsView All Institutional Transactions FLGT Stock Analysis - Frequently Asked Questions Should I buy or sell Fulgent Genetics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FLGT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FLGT, but not buy additional shares or sell existing shares. View FLGT analyst ratings or view top-rated stocks. What is Fulgent Genetics' stock price target for 2024? 2 analysts have issued 12-month price targets for Fulgent Genetics' shares. Their FLGT share price targets range from $25.00 to $35.00. On average, they predict the company's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 38.3% from the stock's current price. View analysts price targets for FLGT or view top-rated stocks among Wall Street analysts. How have FLGT shares performed in 2024? Fulgent Genetics' stock was trading at $28.91 at the beginning of the year. Since then, FLGT stock has decreased by 25.0% and is now trading at $21.69. View the best growth stocks for 2024 here. Are investors shorting Fulgent Genetics? Fulgent Genetics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 611,200 shares, an increase of 22.6% from the February 29th total of 498,400 shares. Based on an average trading volume of 208,900 shares, the short-interest ratio is currently 2.9 days. Currently, 3.2% of the shares of the stock are sold short. View Fulgent Genetics' Short Interest. When is Fulgent Genetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our FLGT earnings forecast. How were Fulgent Genetics' earnings last quarter? Fulgent Genetics, Inc. (NASDAQ:FLGT) issued its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.61. The company had revenue of $70.51 million for the quarter, compared to analysts' expectations of $67.14 million. Fulgent Genetics had a negative net margin of 58.03% and a negative trailing twelve-month return on equity of 3.04%. What ETFs hold Fulgent Genetics' stock? ETFs with the largest weight of Fulgent Genetics (NASDAQ:FLGT) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Global X Genomics & Biotechnology ETF (GNOM), SPDR S&P Health Care Services ETF (XHS) and Invesco S&P SmallCap Health Care ETF (PSCH).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has Fulgent Genetics issued on next quarter's earnings? Fulgent Genetics issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of -1.050--1.050 for the period, compared to the consensus earnings per share estimate of -0.950. The company issued revenue guidance of $280.0 million-$280.0 million, compared to the consensus revenue estimate of $294.2 million. What other stocks do shareholders of Fulgent Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT). When did Fulgent Genetics IPO? Fulgent Genetics (FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers. Who are Fulgent Genetics' major shareholders? Fulgent Genetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (4.88%), Vanguard Group Inc. (4.78%), Vanguard Group Inc. (4.75%), Park West Asset Management LLC (1.43%), Nuveen Asset Management LLC (0.93%) and Charles Schwab Investment Management Inc. (0.90%). Insiders that own company stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv. View institutional ownership trends. How do I buy shares of Fulgent Genetics? Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Fulgent Genetics have any subsidiaries? The following companies are subsidiares of Fulgent Genetics: CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, Fulgent Therapeutics LLC, and Inform Diagnostics.Read More This page (NASDAQ:FLGT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulgent Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.